Ebene-12.jpg
Ebene-10.jpg
Ebene-9.jpg
Ebene-30.jpg
Ebene-11.jpg
Ebene-12.jpg

National umbrella association


From representation of Basel’s pharmaceutical companies to the national umbrella association

SCROLL DOWN

National umbrella association


From representation of Basel’s pharmaceutical companies to the national umbrella association

Interpharma is the association of research-based pharmaceutical companies in Switzerland and was founded in 1933 as an association based in Basel. Historically, Interpharma was an establishment of Switzerland’s big research-based pharmaceutical companies. With the opening-up over the last few years and the resulting sharp increase in membershipto its present number of 24 research-based pharmaceutical companies, Interpharma has grown to become the umbrella association of research-based pharmaceutical companies in Switzerland. The broad support throughout Switzerland strengthens the position of Interpharma to campaign for the international competitiveness of Switzerland as a research and pharmaceutical center. Interpharma collaborates closely with all those involved in the healthcare sector, especially with the research-based pharmaceutical industry lobbies at home and abroad.

Ebene-10.jpg

members 2016


24 member companies with 92% share on the patent-protected market

members 2016


24 member companies with 92% share on the patent-protected market

After the strong growth in membership of the last few years, a new member is joining Interpharma on 1 January 2017 in the shape of Shire. This will bring to 24 the number of Interpharma member companies that make a major contribution to medical progress in general and to improvements in the quality of life for the individual patient with their various treatments and therapies. The market share of Interpharma member companies in the Swiss pharmaceuticals market for patent-protected, reimbursable medicines stands at 92%.

Ebene-9.jpg

Patrons’ Committee, Board, Executive Committee and Management Board


Two decision-making bodies set the strategy and priorities of Interpharma

Patrons’ Committee, Board, Executive Committee and Management Board


Two decision-making bodies set the strategy and priorities of Interpharma

The association structures and governance mechanisms of Interpharma were adapted to the requirements and needs of a growing membership. With the Board and the Executive Committee, Interpharma has two decision-making bodies with clearly defined tasks and competencies. The basis for decision-making is drawn up in the first instance by the nine permanent working groups of Interpharma, to which experts from the member companies contribute their expertise. 

 

PATRONS’ COMMITTEE

  • Jean-Paul Clozel, Actelion
  • Joe Jimenez, Novartis
  • Severin Schwan, Roche

 

BOARD

The Board is the formal decision-making body that decides on the strategy and priorities, as well as the budget of the association. The Board discusses international and pharma political issues, inward investment issues of relevance to the member companies with headquarters in Switzerland or with international functions in Switzerland, as well as questions and standards concerning research and production. Issues and questions that mainly concern the local pharmaceutical market of Switzerland fall within the competence of the Executive Committee.

Board meetings are convened by the Chair three times a year. The Board also has two Vice-Chairs. The Chair of the Executive Committee also sits on the Board. Care is taken to ensure there is balanced representation on the Board for companies with headquarters in Switzerland and international companies with a Swiss subsidiary. The member companies decide on the composition of the Board.
 

  • Pamela Alexa, Pfizer
  • Michael Cobas Meyer, Eli Lilly
  • Thomas B. Cueni, Interpharma
  • Johanna Fiedl-Naderer, Biogen
  • Barbara Heise, Bayer, Vice-Chair
  • Peter Herrmann, Actelion
  • Peter Hug, Roche, Chair
  • Thomas Lang, Merck Sharp & Dohme (MSD)
  • Matthias Leuenberger, Novartis
  • Michelle Lock, Bristol-Myers Squibb
  • Ludo Ooms, Janssen-Cilag
  • Tuomo Pätsi, Celgene
  • Marc Princen, Takeda
  • Doris Seltenhofer, Merck
  • Urban Skog, AstraZeneca
  • Nathalie Stieger, Roche
  • Gianni Zampieri, Vifor

 

EXECUTIVE COMMITTEE

The Executive Committee also has decision-making authority and addresses questions concerning the local pharmaceutical market of Switzerland based on the priorities and guidance of the Board. All member companies are represented on the Executive Committee – usually by the General Manager (GM) of the Swiss subsidiary. The Executive Committee is chaired by the manager of a member company, who is elected by the members. The Executive Committee meets four times a year, although additional meetings may be convened as necessary.

  • Katrin Moser-Schirr, Bristol-Myers Squibb
  • Biljana Naumovic, AstraZeneca
  • Florence Penicaud, UCB
  • Julie Puype-Dehaene, Takeda
  • Natascha Schill, Biogen
  • Doris Seltenhofer, Merck
  • Urban Skog, AstraZeneca, Chair
  • Josef Troxler, Vifor
  • Frank Weber, Janssen-Cilag
  • Olaf Weppner, AbbVie
  • David Werner, Boehringer Ingelheim
  • Oliver Bleck, Roche
  • Daniel Breitenstein, GlaxoSmithKline
  • Etienne Bucher, Actelion
  • Guido Businger, Sanofi
  • Michael Cobas Meyer, Eli Lilly
  • Thomas B. Cueni, Interpharma
  • André T. Dahinden, Amgen
  • Stefanie Granado, Shire
  • Barbara Heise, Bayer
  • Martin Höhener, Pfizer
  • Monika Jänicke, Novartis
  • Thomas Lang, Merck Sharp & Dohme (MSD)
  • Franz J. Lechner, Celgene
  • Urs Lehmann, Lundbeck
  • André Lüscher, Gilead

 

MANAGEMENT

Ebene-30.jpg

Interpharma working groups


More than 150 company experts bring their knowledge to nine working groups

Interpharma working groups


More than 150 company experts bring their knowledge to nine working groups

All member companies can delegate experts to the nine formal working groups of Interpharma and offer their expertise to these groups. The working groups set their priorities based on Board and Executive Committee requirements. These groups are each led by a member of the Executive Committee or by an experienced expert (Chair) and a Vice-Chair. Interpharma provides the working groups with functional support and undertakes all organizational and administrative work. 

Three working groups are concerned with international and national issues: 

  • Animal Welfare Working Group
  • Economic Issues Working Group
  • Intellectual Property Expert Group

The other six working groups address issues concerning the regulatory environment in Switzerland in particular: 

  • Clinical Research Working Group
  • Communications Working Group
  • Good Distribution Practice - Quality Working Group
  • Market Access Working Group
  • Pharmacovigilance Working Group
  • Regulatory Affairs Working Group

Aside from these formal working groups there are also several ad hoc groups that meet as required to work on current issues.

Ebene-11.jpg

Partnerships


An active partner in healthcare and research through cooperation projects

Partnerships


An active partner in healthcare and research through cooperation projects

The broad exchange of ideas on current health and research policy issues and the promotion of public debate on relevant topics is a priority of Interpharma. For this reason, Interpharma cooperates with various actors in the fields of healthcare and research, provides expertise and supports organizations and platforms in planning and holding events, establishing fundamental principles and other activities. In its engagements, Interpharma attaches particular importance to ensuring that the issues are examined from different angles in a pluralistic, contradictory debate.